CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Amiloride Hydrochloride and Hydrochlorothiazide

· ingredient hydrochlorothiazideOther potassium-sparing agents· AMILORIDE HYDROCHLORIDE 5 mg/1; HYDROCHLOROTHIAZIDE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.44788
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other hydrochlorothiazide products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
hydrochlorothiazide$0.01219−$0.43570
hydrochlorothiazide$0.02865−$0.41920
hydrochlorothiazide$0.03324−$0.41460
hydrochlorothiazide$0.04038−$0.40750
Diovan HCT$0.14221−$0.30570
Avalide$0.17972−$0.26820
Micardis HCT$0.36196−$0.08590
spironolactone and hydrochlorothiazide$0.53463+$0.08680

Medicare Part D coverage · CY2026

On 324 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.